Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 1:52 PM
Ignite Modification Date: 2025-12-24 @ 1:52 PM
NCT ID: NCT04733495
Eligibility Criteria: Inclusion Criteria: * Patients with locally advanced human papillomavirus (HPV)+ stage III-IV head and neck (HN) squamous cell carcinomas undergoing concurrent chemotherapy and radiation therapy. Patients with prior cancers or post-surgical patients needing adjuvant therapy will not be allowed to participate in this study * Undergoing planned course of standard of care CRT for a total of 33 to 35 RT fractions (six and a half or seven weeks of treatment) * Adults 18 years old (yo) or older who have clearance from their primary care provider (PCP) or medical oncologist to participate in resistance exercises during treatment. These patients will be monitored very closely on a weekly basis during the trial * All participants must be free of severe heart or systemic disease or medical contraindications that would make supervised RE participation unsafe * Receive medical clearance to participate from treating primary care physician or Medical Oncologists * Ability to understand and the willingness to sign a written informed consent * Willing and physically able to participate in RE Exclusion Criteria: * Severe heart or systemic disease or medical contraindications to exercise * Diagnosis of cancer other than HNCa * Musculoskeletal/Neurological disorder inhibiting them from safe exercise * Pregnant or nursing women * Unable to give informed consent
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT04733495
Study Brief:
Protocol Section: NCT04733495